Selected Publications

Publications abstracts and presentations citing or using TACMASS for the past CCSG funding period 7/1/2003 to 6/30/2008.

  1. Adelman MK, Nagle R, Schluter SF, Marchalonis JJ, Posever JO, Yocum DE. HTLV-1 related endogenous sequence in the etiopathogenesis of Systemic Lupus Erythematosus. Arthritis and Rheumatism. 2004. 50(9):S202,408 (abstract).
  2. Bair EL, Nagle RB, Ulmer TA., Laferte S, Bowden GT. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate. 2006. 66(3):283-93.
  3. Bair EL, Chen ML, McDaniel K, Sekiguchi K, Cress AE, Nagle RB, Bowden GT. Membrane-Type-1 Matrix Metalloproteinase (MT1-MMP) Cleaves Laminin-10 and Promotes Prostate Cancer Cell Invasion. Neoplasia. 2005. 7(4):380-89.
  4. Bredfeldt TG, Jagadish B, Eblin KE, Mash, EA, Gandolfi AJ. 2006.. Monomethylarsonous Acid Induces Transformation of Human Bladder Cells. Toxicol Appl. Pharmacol. 2006. 216(1):69-79.
  5. Buschhorn HM, Klein RR, Chambers SM, Hardy MC, Green S, Bearss D, Nagle RB. Aurora-A over expression in high grade PIN lesions and prostate cancer. The Prostate. 2005. 64:341-46.
  6. Cabello CM, Bair III WB, Wondrak GT. Experimental theraputics: Targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs. 2007. 12:1022-37.
  7. Calaluce R, Bearss D, Barrera J, Zhao Y, Han Y, Beck S, McDaniel K, Nagle RB. Laminin 5 beta 3A expression in LNCaP human prostate carcinoma cells increases cellmigration and tumorigenicity. Neoplasia. 2004. 6:5:468-79.
  8. Chandramouli A, Shi J, Feng Y, Holubec H, Shanas R, Bhattacharyya A, Zheng W, Nelson MA. Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice. Carcinogenesis. 2007. 28(9):2028-35.
  9. Chauhan S, Kunz S, Davis K, Roberts J, Martin G, Demetrious MC, Sroka TC, Cress AE, Meisfeld RL. Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling. J Biol Chem. 2004. 279(2):937-44.
  10. Demetriou MC, Pennington ME, Nagle RB, Cress AE. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res. 2004. 294:550-58.
  11. Dragovich T, McCoy S, Urba S, Zaner K, Benedetti JK, Baker A, Wang, J, Hackett C, Fenoglio-Preiser C, Blanke C Abbruzzese J. SWOG 0127: Phase II Trial of Erlotinib in Gastroesophageal Junction GEJ and Gastric Adenocarcinomas. J Clin Onc. 2006. 24(30):4922-27.
  12. Einspahr JG, Bowden GT, Alberts DS, McKenzie N, Saboda K, Warneke J, Salasche S, Ranger-Moore J, Curiel-Lewandrowski C, Nagle RB, Nickoloff BJ, Brooks C, Dong Z, Stratton SP. Cross-Validation of Murine UV Signal Transduction Pathways in Human Skin. Photochemistry and Photobiology. 2008. 84(2):463-76.
  13. Einspahr JG, Thomas TL, Saboda K., Nickoloff BJ, Warneke J, Curiel-Lewandrowski C, Ranger-Moore J, Duckett L, Bangert J, Fruehauf JP, Alberts DS. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer. 2007. 10:2519-27.
  14. Einspahr JG, Range-Moore J, Warneke J, Saboda K, Bozzo P, Xu MJ, Duckett L., Goldman R, Buckmeier J, Alberts DS. Reproducibility and Expression of Skin Biomarkers in Sun-damaged Skin and actinic keratosis. Cancer Epidemiology, Biomarkers, and Prevention. 2006. 15(10):1841-48.
  15. Frank DH, Roe DJ, Nagle RB, McDaniel KM, Pournajafi-Nazarloo H, Carter S, Weihs K. Role of Oxytocin in Mammary Tumor Development in a Mouse Model. Abstract presented at AACR Pathobiology of Cancer Workshop, July 14-28, 2008.
  16. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomore DA, Borden EC. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J Clin Oncol. 2007. 25(17):2406-13.
  17. Garland L, Rankin C, Scott K, Nagle R, Lobell M, Gandara D, Rivkin S, Samlowski W, Atkins J, Borden E. Molecular Correlates of the EGFR signaling pathway in association with SOWG S0218: A Phase II study of oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). 2003. Abstract, American Society of Clinical Oncology.
  18. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ: Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007. 97:646-53.
  19. Grand CL, Powell TJ, Nagle RB, Bearss DJ, Tye D, Gleason-Guzman M, Hurley LH. Mutations in the G-Quadruplex Silence Element and Their Relationship to c-MYC Overexpression, NM23 expression and Therapeutic Rescue. PNAS. 2004. 101:6140-45.
  20. Hariri LP, Qiu Z, Tumlinson AR, Besselsen DG, Gerner EW, Ignatenko NA, Povazay B, Hermann B, Sattmann H, McNally J, Unterhuber A, Drexler W, Barton JK. Serial Endoscopy in azoxymethane treated mice using ultra-high resolution optical coherence tomography. Cancer Biol Ther. 2007. 6(11):1753-62.
  21. Holly M, Buschhorn S, Chambers M, Hardy PA, Nagle RB. Analysis of Aurora 2 kinase in prostate PIN lesions. Proceedings of the AACR. 2004 March. Vol 45, abstract.
  22. Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Dexter E, Nagle RB, de Alboran IM, Guillen-R JM, Gerner EW. Role of c-Myc in intestinal development and tumorigenesis of the Apc Min/+ mouse. Cancer Biol & Therapeutics. 2006. 5:1658-54.
  23. Ignatenko NA, Holubec H, Besselson DG, Blohm-Mangone KA, Padilla-Tores JL, Dexter EL, Nagle RB, Gerner EW. Role of c-myc in normal intestinal development and tumorigenesis in the Apc Min/+ Mouse. 2005. AACR (abstract).
  24. Jacobson EL, Kim H, Kim M, Williams JD, Coyle DL, Coyle WR, Grove G, Rizer RL, Stratton MS, Jacobson MK. A topical liopophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin. Exp Dermatol. 2007. 16(6)490-99.
  25. Jacobson EL, Kim H, Kim M, Williams JD, Coyle DL, Coyle WR, Grove G, Rizer RL, Stratton M, Jacobson MK. A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin. Journal of Investigative Dermatology. 2007. 68th Annual Meeting (abstract).
  26. Jacobson MK, Kim H, Coyle WR, Kim M, Coyle DL, Rizer RL, Jacobson EL. Effect of Myristyl Nicotinate on Retinoic Acid Therapy for Facial Photodamage. Exp Dermatol. 2007. 16(11):927-35.
  27. Jacobson MK, Kim H, Coyle WR, Kim M, Coyle DL, Rizer RL, Jacobson EL. Myristyl nicotinate mitigates skin barrier impairment and improves tolerability of retinoic acid therapy. Abstract. Journal of Investigative Dermatology. 2007. 68th Annual Meeting (abstract).
  28. Jia L, Liu YJ, Yi X, Liang SX, Miron A, Crum CP, Kong B, Zheng W. Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting its Precancer Nature for Endometrial Serous Carcinoma. Clinical Cancer Res. 2008. 14: 2263-69.
  29. King K, Sukhtankar DD, Vardanyan A, Vanderah TW, Porreca F. A novel model of breast cancer-induced bone pain with mixed osteolytic/osteoblastic bone remodeling. 12th World Congress on Pain (abstract) 2008.
  30. KingT, Vardanyan A, Majuta L, Melemedjian O, Nagle RB, Cress AE, Vanderah TW, Lai J. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain. 2007. 132,154-68.
  31. King T, Vardanyan A, Lai J, Porreca F. Sustained Morphine Enhances Sarcoma-induced Pain and Bone Loss through Opioid Receptors in a Dose Dependent Manner in a Murine Model of Bone Cancer. Skeletal Complications V. 2007. (abstract)
  32. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano G, Nagle RB. 2006. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006. 66(11):1203-12.
  33. Kremer CL, Schmelz M, Cress AE. Integrin-Dependent amplification of the G2 arrest induced by ionizing radiation. Published online The Prostate. 2005. 66(1):88-96.
  34. Lopez J, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res. 2005. 65(15):6755-63.
  35. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle RB, Bearss D. A novel tyrosine kinase switch is a mechanism of Imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007.26(27):3909-19.
  36. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Neri JR, Gray K, Nagle RB, Mazumder A. Quantitative, Spatial Resolution of the Epigenetic Field Effect in Prostate Cancer. Prostate. 2007. 68(2):152-60.
  37. Morse DL, Galons JP, Payne CM, Jennings DL, Day S, Xia G, Gillies RJ. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed. 2007. 20(6):602-14.
  38. Morse D, Galons JP, Payne C, Jennings D, Gillies R. Increased tumor water mobility in response to docetaxel therapy is correlated with multiple cell death mechanisms. Society for Molecular Imaging annual meeting. (abstract) 2006.
  39. Nyman D, Stratton MS, Kopplin M, Dalkin BL, Nagle RB, Gandolfi AJ. Selenium and selenomethionine levels in prostate cancer patients. Cancer Detection and Prevention. 2004. 28:8-16.
  40. Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE. Integrin alpha6 cleavage: A novel modification to modulate cell migration. Exp Cell Res. 2007. 313(6):1080-89.
  41. Pawar SC, Dougherty D, Pennington ME, Demetriou MC, Stea BD, Dorr RT, Cress AE. α6 Integrin Cleavage: Sensitizing human prostate cancer to ionizing radiation. Int J Radiat Biol. 2007. 83(11):1-7.
  42. Pawar S, King T, Porreca F, Nagle RB, Cress AE. Integrin Clipping: Enhancing osetolytic activity in prostate cancer. In Skeletal Complications in Malignancies Conference in Bethesda, MD. (abstract) 2005 April 28-30.
  43. Pochampalli MR, Bitler BG, Schroeder JA. Transforming Growth Factor α-Dependent Cancer Progression is Modulated by Muc1. Cancer Res. 2007. 67(14):6591-98.
  44. Qi W, Liu X, Qiao D, Martinez J. Isoform-Specific Expression of 14-303 Proteins in Human Lung Cancer Tissues. Int J Cancer. 2005. 113:359-63.
  45. Samadzadeh LK, Dexter E, Pestano LA, Cubberley J, Hughes E Jr., Beresford P, Grogan TM, Nagle RB, Pestano GA. Immunohistochemistry Diagnostic Methods: Development of Phospho-protein Detection in Formalin-Fixed Paraffin Embedded (FFPE) Tissues. Poster Abstract presented at Keystone Symposium: Targets for Cancer Therapy. 2005 Jan 6-11. Santa Fe, New Mexico.
  46. Schmelz M, Moll R, Hesse U, Prasad A, Gandolfi J, Hasane S, Bartholdie M, Cress AE. Identification of a stem cell candidate in the normal human prostate gland. Eur J Cell Biol. 2005. 84:341-45.
  47. Simoneau A, Gerner EW, Nagle RB, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H and Meyskens FL Jr. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men. Results of a year long Phase IIb randomized placebo controlled chemoprevention trial. Cancer Epidemiology, Biomarkers and Prevention. 2008. 17:292-99.
  48. Sroka IC, McDaniel K, Nagle RB, Bowden GT. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. The.Prostate. 2008. 68(5):463-76.
  49. Sweetenham JW, Hsi E, Goldman B, LeBlanc M, Tubbs RR, Cook JR, Press OW, Fisher RI, Rimsza LM. Numbers of Lymphoma Associated Macrophages (LAMS) and Regulatory T-Cells in Follicular Lymphoma patients treated with and without monoclonal antibody containing therapy do not correlate with overall survival: A Study from the Southwest Oncology Group (SWOG). Blood. 2007. 110(11):766a.
  50. Vardanyan A, Porreca F, King T. Sustained morphine-induced enhanced sarcoma-induced pain is blocked by NK-1 receptor antagonists. Skeletal Complications V. 2007. (abstract).
  51. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA. Sampliner RE: Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer. 2007 121(10):2132-39.
  52. Yi X, Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Current Opinion Obstet Gynecol, 2008. 20:20-25.
  53. Yi Zhou, Xiaofang Yi, Stoffer JB, Bonafe N, Gilmore-Hebert M, McAlpine J, Chambers SK. The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase: regulation of CSF-1 mRNA stability in ovarian cancer. Accepted, Molecular Cancer Research, 2008.
  54. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The Oncofetal Protein IMP3: A Novel Biomarker for Endometrial Serous Carcinoma. Am J Surg Pathol. 2008. 32:304-15.